Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
Status:
Completed
Trial end date:
2018-04-13
Target enrollment:
Participant gender:
Summary
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318
in healthy subjects following up to 28 days dosing, where F901318 is given orally . The
effect of food upon the pharmacokinetics of F901318 and the effect of F901318 upon the
pharmacokinetics of midazolam will also be assessed.